Courteney Lai Email and Phone Number

Summary of Role: Developed and executed on cell-based assays to quantify antibody effects on in vitro biological function of an array of different antibody targets, supporting program decisions from lead panel to clinical candidate selection. Included data and report presentation to internal teams, preparation of data and figures for presentation to external partners, and training, supervision, and mentorship of own report and junior scientists and techniciansMajor Accomplishments:● Led assay development for co-development partnership, generating data to support down-selection from 39 candidate antibodies to 3 development candidates--Completed development of assay to quantify IgG recycling kinetics by ELISA/MSD in 7 weeks--Designed and engineered five cell line models via lentiviral platforms for assay needs● Lead Biology Assay Driver, leading assay development to support down-selection to 3-6 development candidates for internal T-cell engager program--Quantified cytotoxicity on 5 tumour cell lines (xCelligence, high-content imaging) and T cell kinetics (flow cytometry, cytokine release by MSD)● Translational Biology In Vitro Biology Lead on a cross-functional team for internal development program--Designed workplans to develop and execute assays to support building a comprehensive picture of our lead molecule--Developed a confocal microscopy assay to quantify antibody internalization kinetics● Co-founded company-wide Flow Cytometry Community of Practice, a community of flow cytometry users to support each other, share technical knowledge, troubleshoot, and showcase innovative advancements at AbCellera● Selected to participate in AbCellera’s Foundational Leadership Program (The Coaching Studio) ● Oversaw hiring for 4 junior roles on the team; supported hiring of team members at all levels (expanding team from 8 to 25 members) and for other teams

Summary of Role: Initiated and developed platform capabilities requiring specific engineering of mammalian cell lines to support expansion of company capabilities. Included generating ideas for and authoring platform development proposals, design, generation, and characterisation of cell lines generated, data and report presentation to internal teams, and training, supervision, and mentorship of junior scientists and technicians.Major Accomplishments:● Co-initiated lentiviral cell line generation platform development capabilities AbCellera, resulting in creation of Cell Line Core● Co-designed and led generation of 13 lentiviral vector constructs to generate cell lines with varying expression levels of gene of interest on 2 parental cell line backgrounds for tumour-directed cell cytotoxicity (TDCC) assay development for internal T cell engager program● Supported design and generation of 12 bulk and clonal cell lines (4 vector designs) on 2 parental cell line backgrounds for use in cell-based assay development for co-development project with external partner● Drove evaluation of clonal and oligoclonal cell line development workflows as part of company-wide evaluation of Lonza GS-CHO system● Established guidelines and processes for in-house characterisation of growth and infectivity properties of newly-acquired cell lines● Participated in establishment of company-wide standardized mycoplasma testing for cells in collaboration with Lab Management team● Trained 3 team members in principles of flow cytometry and FlowJo analysis● Supported early pseudoneutralisation assay platform development● Supported hiring of 2 junior team member

Interrogated combined genetic vulnerability and drug sensitivity in AML to identify and characterise targetable pathways● Generated and established an AML-specific 67 shRNA lentivirus library for screening with specific drug treatments in cell line models, ex vivo patient-derived xenograft (PDF) models, primary cord blood, and AML patient samples● Established long-read Oxford Nanopore Sequencing in the lab as a rapid diagnostic tool for complex karyotype AML and MDS with academic and industry collaborators at the Charité University Hospital in Berlin and Jazz Pharmaceuticals● Mentored 2 PhD students● Awarded University-Internal Performance Promotion Grant for Early Career Scientists (HiLF I) research grant funding (25,000 euros)Key

Extension of PhD work to characterise the role of the transcriptional co-factor Meis2 in MN1-induced leukemia using human and murine cell line and murine in vivo modelsKey

Supervisor: Dr. R. Keith Humphries (Co-Supervisor: Dr. Sam A. Aparicio)Thesis Title: Insights into leukemogenesis in a MN1-induced leukemia model● Investigated contributions of specific protein regions of single-hit acute myeloid leukemia model to leukemic characteristics, and to elucidate genes and transcriptional pathways critical to leukemic stem cell function using human and murine cell line and murine in vivo models ● Supervised and mentored 2 co-op students● Supported hiring of >10 co-op students and 3 post-doctoral fellows● >$110,000 funding secured during PhDKey skills: cytotoxicity assays, proliferation/cell cycle assays, apoptosis assays, shRNA/siRNA library screening, retrovirus/lentivirus generation & transduction, flow cytometry, mammalian cell culture, western blot, CFU assays, qRT-PCR, fluorescence microscopy, confocal microscopy, IV/IP/SubQ injections, in vivo murine studies

● Interrogated transcriptional gene regulation in leukemic cells to identify cell signaling pathways involved in self-renewal ● Investigated the roles and functions of the meningioma 1 (MN1) oncogene in acute myeloid leukemia using human and murine cell line and murine in vivo modelsKey

● Evaluated cell culture systems as small-scale models for optimising Rituximab production using shake-flask and bioreactor systems to monitor parameters including cell growth, cell viability, and antibody titers● Supported Late Stage Cell Culture (Process Development) group research goals to support FDA filings (small-scale bioreactors, HPLC)